Document:

Executive Employment Agreement

 Exhibit 10.1 

EXECUTIVE EMPLOYMENT AGREEMENT 

This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 12, 2010, by and between Inspire
Pharmaceuticals, Inc. (together with its successors and assigns, “Inspire” or the “Company”), and Charles Johnson (“Executive”). 

R E C I T A L S 

WHEREAS, the Company desires to employ Executive and Executive desires to be employed by the Company as the Company’s Executive Vice
President of Research and Development and Chief Medical Officer. 
 NOW, THEREFORE, in consideration of the foregoing recitals,
the mutual covenants and conditions herein, and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereby agree as follows: 

A G R E E M E N T 

1. Employment and Term. The Company hereby agrees to employ Executive and Executive hereby accepts employment by the Company on
the terms and conditions hereinafter set forth. Executive’s term of employment by the Company under this Agreement (the “Term”) shall commence on September 15, 2010 or such earlier date as the parties may mutually
agree (the “Effective Date”) and continue through December 31, 2015; provided, however, that the Term shall thereafter be automatically extended for unlimited additional one-year periods unless, at least three
months prior to the then-scheduled date of expiration of the Term, either (a) the Company gives notice to Executive that it is electing not to so extend the Term or (b) Executive gives notice to the Company that he is electing not to so
extend the Term. Notwithstanding the foregoing, the Term may be earlier terminated in strict accordance with the provisions of Section 5 below, in which event Executive’s employment with the Company shall expire in accordance therewith.

 2. Position, Duties and Responsibilities; Location. 

2.1 Position and Duties. Executive shall be employed as Executive Vice President of Research and Development and Chief Medical
Officer of the Company. Executive shall have, subject to the general direction of the President and Chief Executive Officer of the Company (the “CEO”), general overall authority and responsibility for the day-to-day management
of the research and development functions of the Company. Executive shall also have such other duties, powers and authority as are commensurate with his position as an executive vice president of research and development or chief medical officer of
a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products, including such other duties and responsibilities as are reasonably delegated to him from time to time by the CEO. Executive
shall report to the CEO. 

 2.2 Exclusive Services and Efforts. Executive agrees to devote his efforts, energies
and skill to the discharge of the duties and responsibilities attributable to his position and, except as set forth herein, agrees to devote substantially all of his professional time and attention exclusively to the business and affairs of the
Company. It is expressly understood and agreed that, during the Term, Executive will not be employed by, render services to, or represent, any other person, firm or company engaged in a business of a similar nature or in competition with the Company
without the prior written consent of the Company. Executive also agrees that he shall not take personal advantage of any business opportunities which arise during his employment and which may benefit the Company and are within the scope of the
Company’s then business or natural extension thereof without the consent of the Company, provided, that the foregoing does not apply to future employment opportunities. Notwithstanding the foregoing, Executive shall be entitled to
(a) engage in service on the board of directors of not-for-profit organizations, provided that he has received the prior written approval of the Company’s Board of Directors (the “Board”), (b) engage in other charitable
activities and community affairs, and (c) manage his personal and family investments and affairs, in each case to the extent such activities do not, either individually or in the aggregate, materially interfere with the performance of his
duties and responsibilities to the Company. 
 2.3 Compliance with Company Policies. To the extent not inconsistent with
the terms and conditions of this Agreement and with due regard for his position, Executive shall be subject to the bylaws, policies, practices, procedures and rules of the Company, including those policies and procedures specified in the
Company’s Employee Handbook. 
 2.4 Location. Executive’s principal office, and principal place of employment,
shall be at the Company’s principal executive offices, which shall initially be in Durham, North Carolina and are expected to move to Raleigh, North Carolina in January 2011. 

3. Compensation. 

3.1 Base Salary. Commencing on the Effective Date and continuing through the duration of the Term, the Company hereby agrees to
pay to Executive an annualized base salary of Three Hundred Ninety-Five Thousand Dollars ($395,000) (the “Salary”) payable in equal installments on the Company’s regularly-scheduled paydays as it is earned, subject to all
applicable federal, state and local income and employment taxes and other required or elected withholdings and deductions. Executive’s Salary will be reviewed at least annually by the compensation committee (the “Compensation
Committee”) of the Board, or the full Board, commencing in January 2011 and may be adjusted by the Compensation Committee or the Board (in which case such new amount shall be the “Salary” hereunder). 

3.2 Cash Bonuses. 

(a) Annual Cash Bonus. For each calendar year that ends during the Term, Executive shall be eligible to receive an annual target
cash bonus opportunity of 50% of base salary. The annual cash bonus is awarded at the good faith discretion of the Compensation 

 

 2 

 
Committee, based upon the Compensation Committee’s evaluation of the Company’s performance and the Executive’s performance, in accordance with the terms and conditions of the
Company’s Executive Officer Annual Cash Bonus Plan and any other applicable bonus plan in effect upon the Effective Date and during the remainder of the Term. For 2010, Executive shall be guaranteed an annual cash bonus (payable in 2011 in
accordance with the Company’s Executive Officer Cash Bonus Plan) equal to his target bonus pro rated to reflect the portion of the year during which Executive was employed by the Company. 

(b) Sign-On Bonus. Subject to the commencement of employment on the Effective Date, the Company shall pay to Executive a lump sum
cash bonus in the amount of One Hundred Fifty Thousand Dollars ($150,000) (the “Sign-On Bonus”) within sixty (60) days following the Effective Date. 

3.3 Equity Compensation. 

(a) Long Term Incentive Compensation. Executive will be eligible for grants of long-term incentive and equity compensation awards
at the same time as other similarly situated executives of the Company in 2011 and thereafter during the Term at the good faith discretion of the Compensation Committee, based upon the Compensation Committee’s evaluation of his performance and
peer company compensation practices, in accordance with the terms and conditions of the Company’s Amended and Restated Equity Compensation Grant Policy and any other applicable policy in effect upon the Effective Date and during the remainder
of the Term. 
 (b) Sign-On Awards. On the Effective Date, the Company shall grant to Executive an award of 150,000
Restricted Stock Units (the “Sign-On RSUs”) and options to purchase 250,000 shares of Common Stock (the “Sign-On Options”). The Sign-On RSUs will vest 25% on the first anniversary of the Effective Date and the
remainder shall then vest ratably on an annual basis over the next three years on the respective anniversary dates of the Effective Date. The Sign-On Options will vest 25% on the first anniversary of the Effective Date and the remainder shall then
vest ratably over the next three years in thirty-six (36) monthly installments after the first anniversary of the Effective Date until fully vested. 

4. Employee Benefits. 

4.1 Participation in Benefit Plans. During the Term, Executive shall be entitled to participate in such health, group insurance,
welfare, pension, and other employee benefit plans, programs and arrangements as are made generally available from time to time to senior executives of the Company (which shall include health, life insurance and disability plans), such participation
in each case to be on terms and conditions no less favorable to Executive than to other senior executives of the Company generally. 

4.2 Vacations; Other. During the Term, Executive shall be entitled to participate in other benefits made available generally to
other senior executives of the Company, such participation to be at levels, and on terms and conditions, that are commensurate with his 

 

 3 

 
position and responsibilities at the Company and that are no less favorable than those applying generally to other senior executives at similar levels of the Company. In addition, Executive shall
be entitled to twenty (20) days paid vacation per calendar year (which, if not used, may be carried over from year to year). Executive shall also be entitled to participate in the Company’s Executive Change in Control Severance Benefit
Plan as, and to the extent, in effect from time to time. 
 4.3 Reimbursement of Expenses. The Company shall reimburse
Executive for all reasonable business and travel expenses, incurred in the performance of his job duties and the promotion of the Company’s business, promptly upon presentation of appropriate supporting documentation and otherwise in accordance
with the expense reimbursement policy of the Company. 
 4.4 Relocation Expenses. Relocation expenses will be reimbursed
up to $250,000 in accordance with the Company’s standard policies. In the event Executive’s employment with the Company terminates for Cause or without Good Reason within twelve (12) months of the Effective Date, Executive shall repay
to the Company all amounts previously paid to Executive in connection with the Sign-On Bonus and any and all relocation expenses. In the event Executive’s employment with the Company terminates for Cause or without Good Reason after the twelfth
(12th) month from the Effective Date but prior to the end of the twenty-fourth (24th) month from the Effective Date, Executive shall repay to the Company fifty percent (50%) of the Sign-On Bonus and fifty percent (50%) of any and
all relocation expenses previously paid. 
 5. Termination. 

5.1 General. The Company may terminate Executive’s employment for any reason or no reason, and Executive may terminate his
employment for any reason or no reason, in either case subject only to the terms of this Agreement. For purposes of this Agreement, the following terms have the following meanings: 

(a) “Accrued Obligations” shall mean: (i) Executive’s earned but unpaid Salary through the Termination Date
(as hereinafter defined); (ii) payment of any annual, long-term, or other incentive award with respect to which all required performance periods have been completed and all required performance and service conditions have been satisfied on or
before the Termination Date; (iii) payment in respect of accrued but unused vacation days in accordance with the Company’s vacation policies; and (iv) any unpaid expense or other reimbursement due pursuant to Sections 4.2 or 4.3
hereof or otherwise. 
 (b) “Cause” shall mean (i) the deliberate and continued failure by Executive to
devote substantially all of his business time and best efforts to the performance of Executive’s duties after a demand for substantial performance is delivered to Executive by the Board which specifically identifies the manner in which
Executive has not substantially performed such duties; (ii) the engaging by Executive in gross misconduct which is injurious to the Company, monetarily or otherwise, including but not limited to, fraud or embezzlement by

  

 4 

 
Executive; or (iii) Executive’s conviction (or entering into a plea bargain admitting guilt) of any felony. 

(c) “Company Arrangement” shall mean any plan, program, agreement, corporate governance document or arrangement of the
Company. 
 (d) “Disability” shall mean total and permanent disability as defined in the Company’s
long-term disability plan. 
 (e) “Good Reason” shall mean the occurrence of any one of the following events
without either (x) Executive’s express prior written consent or (y) full cure within thirty (30) days after Executive gives written notice to the Company: (i) a reduction, other than a temporary one, in Executive’s
authority, duties, responsibilities, or reporting lines; (ii) a reduction by the Company in Executive’s Salary, except for (A) across-the-board salary reductions similarly affecting all salaried employees of the Company or
(B) across-the-board salary reductions similarly affecting all senior executive officers of the Company; (iii) the relocation of Executive’s principal office, or principal place of employment, to a location more than fifty
(50) miles from Durham, North Carolina; or (iv) any other action or inaction that constitutes a material breach of this Agreement, provided however, that no event shall constitute grounds for a Good Reason termination unless Executive
terminates his employment within one year after such event occurs. 
 (f) “Person” shall mean any individual,
corporation, partnership, limited liability company, joint venture, trust, estate, board, committee, agency, body, employee benefit plan, or other person or entity. 

(g) “Pro-Rata Annual Cash Bonus” shall mean an amount equal to (i) the annual cash bonus that Executive would have
been entitled to receive for the calendar year during which his employment hereunder terminated if his employment hereunder had continued (such amount to be determined with any subjective or personal performance goals rated at no less than target),
multiplied by (ii) a fraction, the numerator of which is the number of days he was employed hereunder during such year and the denominator of which is the number of days in such year. 

(h) “Termination Date” shall mean the date on which Executive’s employment hereunder terminates in accordance with
this Agreement (which, in the case of a notice of non-renewal of the Term in accordance with Section 1 hereof, shall mean the date on which the Term expires). 

(i) “Vested Options” shall mean all outstanding vested stock options held by Executive on the Termination Date.

 5.2 Termination by the Company without Cause or by Executive for Good Reason. In the event that Executive’s
employment is terminated by the Company without Cause 
  

 5 

 
or by Executive for Good Reason, the Term shall expire on the Termination Date and Executive shall be entitled to: 

(a) a cash amount, payable in equal installments in accordance with the Company’s regular payroll policies following his
Termination Date, in an amount equal to the sum of (i) his Salary as in effect immediately prior to the Termination Date and (ii) a Pro-Rata Annual Cash Bonus; 

(b) the post-termination exercise period for all Vested Options shall be extended to the earlier of (i) the first anniversary of
the Termination Date, and (ii) the date of expiration of the respective option. Except as specifically provided for in this Agreement, all other terms of the Vested Options shall remain unchanged. All outstanding stock options granted to
Executive prior to the Termination Date that are not Vested Options shall be terminated as of the Termination Date; 
 (c)
continued health benefits under the Consolidated Budget Reconciliation Act of 1984, as amended, subsidized at active employee rates for a period of one year from the first day of the month following the Executive’s Termination Date; 

(d) outplacement services for a period of twelve (12) months following the Termination Date; and 

(e) the Accrued Obligations. 

5.3 Death and Disability. Executive’s employment shall terminate in the event of his death, and either
Executive or the Company may terminate Executive’s employment in the event of his Disability (provided that no termination of Executive’s employment hereunder for Disability shall be effective unless the party terminating Executive’s
employment first gives at least fifteen (15) days’ written notice of such termination to the other party). In the event that Executive’s employment hereunder is terminated due to his death or Disability, the Term shall expire on the
Termination Date and he and/or his estate or beneficiaries (as the case may be) shall be entitled to (a) a single sum cash amount, payable on the
60th day following the Termination Date, in an amount
equal to a Pro-Rata Annual Cash Bonus, (b) the benefits described in Section 5.2(b) and (c) the Accrued Obligations. 

5.4 Termination by the Company for Cause or by Executive Without Good Reason. In the event that Executive’s employment
hereunder is terminated by Executive without Good Reason or by the Company for Cause, the Term shall expire as of the Termination Date and Executive shall only be entitled to the Accrued Obligations. 

5.5 Expiration of the Term. Executive or the Company may elect not to renew or extend the Term in accordance with Section 1
above, in which case the Termination Date shall be the date the Term expires. In the event of such a termination, Executive shall only be entitled to the Accrued Obligations. 

 

 6 

 5.6 Termination Due to Change in Control. Executive will be eligible for compensation
in accordance with the terms and conditions of the Company’s Executive Change in Control Severance Benefit Plan, as in effect from time to time. 

5.7 Release. Executive’s entitlement to the payments described in this Section 5 is expressly contingent upon Executive
first providing the Company with a signed mutual release in substantially the form attached hereto as Exhibit A (the “Release”) and not revoking such release for a period of seven days after its execution or
thereafter and is also contingent upon Executive’s continued compliance with the Non-Compete Agreement (defined in Section 7 below). In order to be effective, such Release must be (a) delivered by Executive to the Company no later
than forty-five (45) days following the Termination Date and (b) counter-signed and returned by the Company to Executive within ten (10) days following the Company’s receipt thereof; provided, however, that if
Executive delivers the Release to the Company on a timely basis and the Company does not return a counter-signed Release during the applicable time period allowed, such Release of Executive shall be null and void and the payments hereunder shall
cease to be contingent on the Release and this Section 5.7. 
 6. Other Tax Matters. 

6.1 The Company shall withhold all applicable federal, state and local taxes, workers’ compensation contributions and other amounts
as may be required by law with respect to compensation payable to Executive pursuant to this Agreement. 
 6.2 Notwithstanding
anything herein to the contrary, this Agreement is intended to be interpreted and applied so that the payment of the benefits set forth herein shall either be exempt from the requirements of Section 409A of the Code (“Section
409A”) or shall comply with the requirements of such provision. Notwithstanding any provision of this Agreement to the contrary, if Executive is a “specified employee” (within the meaning of Section 409A), any payments or
arrangements due upon a termination of Executive’s employment under any arrangement that constitutes a “nonqualified deferral of compensation” (within the meaning of Section 409A) and which do not otherwise qualify under the
exemptions under Treas. Regs. Section 1.409A-1 (including without limitation, the short-term deferral exemption or the permitted payments under Treas. Regs. Section 1.409A-1(b)(9)(iii)(A)), shall be delayed and paid or provided on the
earlier of (i) the date which is six months after Executive’s “separation from service” (as such term is defined in Section 409A and the regulations and other published guidance thereunder) for any reason other
than death, and (ii) the date of Executive’s death. 
 6.3 After any Termination Date, Executive shall have no
duties or responsibilities that are inconsistent with having a “separation from service” (within the meaning of Section 409A) as of the Termination Date and, notwithstanding anything in the Agreement to the contrary, distributions
upon termination of employment of nonqualified deferred compensation may only be made upon a “separation from service” (as determined under Section 

 

 7 

 
409A) and such date shall be the Termination Date for purposes of this Agreement. Each payment under this Agreement or otherwise shall be treated as a separate payment for purposes of
Section 409A. In no event may Executive, directly or indirectly, designate the calendar year of any payment to be made under this Agreement which constitutes a “nonqualified deferral of compensation” (within the meaning of
Section 409A) and to the extent an amount is payable within a time period, the time during which such amount is paid shall be in the discretion of the Company. 

6.4 Any amounts otherwise payable to Executive following a termination of employment that are not so paid by reason of this
Section 6 shall be paid as soon as practicable following, and in any event within thirty (30) days following, the date that is six (6) months after Executive’s separation from service (or, if earlier, the date of
Executive’s death) together with interest on the delayed payment at the Company’s cost of borrowing. All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of
Section 409A. 
 6.5 To the extent that any reimbursements pursuant to Section 4 or otherwise are taxable to
Executive, any reimbursement payment due to Executive pursuant to such Section shall be paid to Executive on or before the last day of Executive’s taxable year following the taxable year in which the related expense was incurred. The
reimbursements pursuant to Section 4 or otherwise are not subject to liquidation or exchange for another benefit and the amount of such reimbursements that Executive receives in one taxable year shall not affect the amount of such
reimbursements that Executive receives in any other taxable year. 
 7. Confidentiality, Invention Assignment and
Non-Competition Agreement. Executive agrees to be bound by the terms of the Employee Confidentiality, Invention Assignment and Non-Compete Agreement, a copy of which is attached hereto as Exhibit B and incorporated herein by reference
(the “Non-Compete Agreement”). Except as expressly set forth in this Agreement and the Non-Compete Agreement, Executive shall be subject to no contractual or similar restrictions on his right to terminate his employment
hereunder or on his activities after the Termination Date. 
 8. Non-Disparagement. During and after the Term, Executive
and the Company agree not to make any statement that criticizes, ridicules, disparages, or is otherwise derogatory of the other; provided, however, that nothing in this Agreement shall restrict either party from making truthful statements
(a) when required by law, subpoena, court order or the like; (b) when requested by a governmental, regulatory, or similar body or entity; (c) in confidence to a professional advisor for the purpose of securing professional advice;
(d) in the course of performing his or its duties during the Term; (e) from rebutting any statement made or written about him or it; or (f) from making normal competitive statements about the Company’s business or products.

  

 8 

 9. Notices. Except as otherwise specifically provided herein, any notice, consent,
demand or other communication to be given under or in connection with this Agreement shall be in writing and shall be deemed duly given when delivered personally, when transmitted by facsimile transmission, one (1) day after being deposited
with Federal Express or other nationally recognized overnight delivery service or three (3) days after being mailed by first class mail, charges or postage prepaid, properly addressed, if to the Company, at its principal office, and, if to
Executive, at his address provided by separate notice to the Company. Either party may change such address from time to time by notice to the other. 

10. Governing Law. This Agreement shall be governed by and construed and interpreted in accordance with the laws of the State of
North Carolina, exclusive of any choice of law rules. 
 11. Arbitration; Legal Fees. 

11.1 Any dispute or controversy arising under or in connection with this Agreement (except with respect to injunctive relief under
Section 10 of the Non-Compete Agreement) shall be settled exclusively by arbitration in North Carolina, in accordance with the rules of the American Arbitration Association for employment disputes as then in effect. Judgment may be entered on
the arbitrator’s award in any court having jurisdiction. 
 11.2 In the event of any material contest or dispute relating
to this Agreement or the termination of Executive’s employment hereunder, each of the parties shall bear its own costs and expenses, except that the Company agrees to promptly reimburse Executive for his costs and expenses (including reasonable
attorneys’ fees and expenses) incurred by Executive in connection with such contest or dispute in the event Executive prevails, as determined by the arbitrator if in arbitration, by the court if pursuant to Section 9 of the Non-Compete
Agreement, or as a separate arbitration if otherwise. The amount shall be paid within thirty (30) days of the award of the arbitration or court, which shall also specify the amount due. 

12. Amendments; Waivers. This Agreement may not be modified or amended or terminated except by an instrument in writing, signed by
Executive and a duly-authorized officer of the Company (other than Executive). By an instrument in writing similarly executed, either party may waive compliance by the other party with any provision of this Agreement that such other party was or is
obligated to comply with or perform; provided, however, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure. No failure to exercise and no delay in exercising any right,
remedy, or power hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, or power hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, or power
provided herein or by law or in equity. To be effective, any written waiver must specifically refer to the condition(s) or provision(s) of this Agreement being waived. 

13. Inconsistencies. In the event of any inconsistency between any provision of this Agreement and any provision of any Company
arrangement, the provisions of this Agreement 
  

 9 

 
shall control, unless Executive and the Company otherwise agree in a writing that expressly refers to the provision of this Agreement that is being waived. 

14. Assignment. Except as otherwise specifically provided herein, neither party shall assign or transfer this Agreement nor any
rights hereunder without the consent of the other party, and any attempted or purported assignment without such consent shall be void; provided, however, that any assignment or transfer pursuant to a merger or consolidation, or the
sale or liquidation of all or substantially all of the business and assets of the Company shall be valid, so long as the assignee or transferee (a) is the successor to all or substantially all of the business and assets of the Company and
(b) assumes the liabilities, obligations and duties of the Company, as contained in this Agreement, either contractually or as a matter of law. Executive’s consent shall not be required for any such transaction. This Agreement shall
otherwise bind and inure to the benefit of the parties hereto and their respective successors, penalties, assigns, heirs, legatees, devisees, executors, administrators and legal representatives. 

15. Voluntary Execution; Representations. Executive acknowledges that (a) he has consulted with or has had the
opportunity to consult with independent counsel of his own choosing concerning this Agreement and has been advised to do so by the Company and (b) he has read and understands this Agreement, is competent and of sound mind to execute this
Agreement, is fully aware of the legal effect of this Agreement, and has entered into it freely based on his own judgment and without duress. Executive represents and covenants that his employment hereunder and compliance with the terms and
conditions hereof will not conflict with or result in the breach by him of any agreement to which he is a party or by which he may be bound and in connection with his employment with the Company he will not engage in any unauthorized use of any
confidential or proprietary information he may have obtained in connection with his employment with any other employer. The Company represents and warrants that it is fully authorized, by any person or body whose authorization is required, to enter
into this Agreement and to perform its obligations under it. 
 16. Headings. The headings of the Sections and
sub-sections contained in this Agreement are for convenience only and shall not be deemed to control or affect the meaning or construction of any provision of this Agreement. 

17. Beneficiaries/References. Executive shall be entitled, to the extent permitted under applicable law, to select and change a
beneficiary or beneficiaries to receive any compensation or benefit hereunder following Executive’s death by giving written notice thereof. In the event of Executive’s death or a judicial determination of his incompetence, references in
this Agreement to Executive shall be deemed, where appropriate, to refer to his beneficiary, estate or other legal representative. 

18. Survivorship. Except as otherwise set forth in this Agreement, the respective rights and obligations of the parties shall
survive any termination of Executive’s employment. 
  

 10 

 19. Severability. Whenever possible, each provision or portion of any provision of
this Agreement will be interpreted in such manner as to be effective and valid under applicable law but the invalidity or unenforceability of any provision or portion of any provision of this Agreement in any jurisdiction shall not affect the
validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of this Agreement, including that provision or portion of any provision, in any other jurisdiction. 

20. No Mitigation/No Offset. Executive shall be under no obligation to seek other employment or to otherwise mitigate the
obligations of the Company under this Agreement, and there shall be no offset against amounts or benefits due to Executive under this Agreement or otherwise on account of any claim (other than any preexisting debts then due in accordance with their
terms) the Company may have against him or any remuneration or other benefit earned or received by Executive after such termination. 

21. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all
such counterparts shall together constitute one and the same instrument. Signatures delivered by facsimile or e-mail (as a .pdf, .tif or similar un-editable attachment) shall be effective for all purposes. 

22. Entire Agreement. This Agreement, the Non-Compete Agreement and the agreements described in the attached Exhibits contain the
entire agreement of the parties and supersedes all prior or contemporaneous negotiations, correspondence, understandings and agreements between the parties, regarding the subject matter of this Agreement. 

[Signature Page to Follow] 
  

 11 

 IN WITNESS WHEREOF, this Agreement has been duly executed by or on behalf of the parties
hereto as of the date first above written. 
  

			
	INSPIRE PHARMACEUTICALS, INC.:
		
	By:	 	 /s/ Adrian Adams

	Name:	 	Mr. Adrian Adams
	Title:	 	President & CEO
	
	EXECUTIVE:
	
	 /s/ Charles Johnson

	Name:	 	Charles Johnson

  

 12 

 Exhibit A 

FORM OF GENERAL RELEASE OF ALL CLAIMS 

THIS GENERAL RELEASE OF ALL CLAIMS (this “General Release”), dated as of
[                        ], is made by and between
[            ] (the “Executive”) and Inspire Pharmaceuticals, Inc. (the “Company”). 

WHEREAS, the Company and Executive are parties to that certain Employment Agreement, dated as of
[            ], 2010 (the “Employment Agreement”); 

WHEREAS, Executive’s employment with the Company has been terminated and Executive is entitled to receive severance and other
benefits, as set forth in Section 5 of the Employment Agreement subject to the execution of this General Release; 

WHEREAS, in consideration for Executive’s signing of this General Release, the Company will provide Executive with such severance
and benefits pursuant to the Employment Agreement; and 
 WHEREAS, except as otherwise expressly set forth herein, the parties
hereto intend that this General Release shall effect a full satisfaction and release of the obligations described herein owed to Executive by the Company and to the Company by Executive. 

NOW, THEREFORE, in consideration of the premises, the mutual covenants of the parties hereinafter set forth and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby covenant and agree as follows: 
 1.
Executive, for himself, Executive’s spouse, heirs, administrators, children, representatives, executors, successors, assigns, and all other individuals and entities claiming through Executive, if any (collectively, the “Executive
Releasers”), does hereby release, waive, and forever discharge the Company and each of its respective agents, subsidiaries, parents, affiliates, related organizations, employees, officers, directors, attorneys, successors, and assigns in
their capacities as such (collectively, the “Employer Releasees”) from, and does fully waive any obligations of Employer Releasees to Executive Releasers for, any and all liability, actions, charges, causes of action, demands,
damages, or claims for relief, remuneration, sums of money, accounts or expenses (including attorneys’ fees and costs) of any kind whatsoever, whether known or unknown or contingent or absolute, which heretofore has been or which hereafter
may be suffered or sustained, directly or indirectly, by Executive Releasers in consequence of, arising out of, or in any way relating to: (a) Executive’s employment with the Company; (b) the termination of Executive’s
employment with the Company; (c) the Employment Agreement; or (d) any events occurring on or prior to the date of this General Release. The foregoing release and discharge, waiver and covenant not to sue includes, but is not
limited to, all waivable claims and any obligations or causes of action arising from such claims, under common law including wrongful or retaliatory discharge, breach of contract (including but not limited to any claims under the Employment
Agreement other than claims for unpaid severance 
  

 13 

 
benefits, bonus or Base Salary earned thereunder) and any action arising in tort including libel, slander, defamation or intentional infliction of emotional distress, and claims under any
federal, state or local statute including the Age Discrimination in Employment Act (“ADEA”), Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1866 and 1871 (42 U.S.C. § 1981), the National Labor
Relations Act, the Fair Labor Standards Act, the Employee Retirement Income Security Act, the Americans with Disabilities Act of 1990, the Rehabilitation Act of 1973, or the discrimination or employment laws of any state or municipality, and/or any
claims under any express or implied contract which Executive Releasers may claim existed with Employer Releasees. This also includes a release of any claims for wrongful discharge and all claims for alleged physical or personal injury, emotional
distress relating to or arising out of Executive’s employment with the Company or any of its subsidiaries or affiliates or the termination of that employment; and any claims under the WARN Act or any similar law, which requires, among other
things, that advance notice be given of certain work force reductions. Notwithstanding anything contained in this Section 1 above to the contrary, nothing contained herein shall constitute a release by any Executive Releaser of any of
his, her or its rights or remedies available to him, her or it, at law or in equity, related to, on account of, in connection with or in any way pertaining to the enforcement of: (i) any rights to the receipt of employee benefits which
vested on or prior to the date of this General Release; (ii) the right to receive severance and other benefits under the Employment Agreement; (iii) the right to continuation coverage pursuant to the Consolidated Omnibus Budget
Reconciliation Act; (iv) any rights of Executive under the Employment Agreement with respect to (A) the gross-up protections set forth in Section 7 of the Employment Agreement, and (B) any equity rights; or
(v) this General Release or any of its terms or conditions. 
 2. Excluded from this General Release and waiver are any claims which
cannot be waived by applicable law, including but not limited to the right to participate in an investigation conducted by certain government agencies. Executive does, however, waive Executive’s right to any monetary recovery should any
government agency (such as the Equal Employment Opportunity Commission) pursue any claims on Executive’s behalf. Executive represents and warrants that Executive has not filed any complaint, charge, or lawsuit against the Employer Releasees
with any government agency or any court. 
 3. Executive agrees never to seek personal recovery from any Employer Releasee in any forum for any
claim covered by the above waiver and release language, except that Executive may bring a claim under the ADEA to challenge this General Release. If Executive violates this General Release by suing an Employer Releasee (excluding any claim by
Executive under the ADEA or as otherwise set forth in Section 1 hereof), then Executive shall be liable to the Employer Releasee so sued for such Employer Releasee’s reasonable attorneys’ fees and other litigation costs
incurred in defending against such a suit. Nothing in this General Release is intended to reflect any party’s belief that Executive’s waiver of claims under ADEA is invalid or unenforceable, it being the intent of the parties that such
claims are waived. 
 4. Each party agrees that neither this General Release, nor the furnishing of the consideration for this General Release,
shall be deemed or construed at any time to be an admission by any party of any improper or unlawful conduct. 
 5. Each party acknowledges and
recites that he or it has: 
  

 14 

 (a) executed this General Release knowingly and voluntarily; 

(b) had a reasonable opportunity to consider this General Release; 

(c) read and understands this General Release in its entirety; 

(d) been advised and directed orally and in writing (and this subparagraph (d) constitutes such written direction) to seek
legal counsel and any other advice such party wishes with respect to the terms of this General Release before executing it; and 

(e) relied solely on such party’s own judgment, belief and knowledge, and such advice as such party may have received from such
party’s legal counsel. 
 6. Section 11 of the Employment Agreement, which shall survive the expiration of the Employment Agreement
for this purpose, shall apply to any dispute with regard to this release. 
 7. Executive acknowledges and agrees that
(a) his execution of this General Release has not been forced by any employee or agent of the Company, and Executive has had an opportunity to negotiate the terms of this General Release and (b) he has been offered twenty-one
(21) calendar days after receipt of this General Release to consider its terms before executing
it.1 Executive shall have seven (7) calendar days
from the date he executes this General Release to revoke his or her waiver of any ADEA claims by providing written notice of the revocation to the Company, as provided in Section 11 of the Employment Agreement. 

8. Capitalized terms used but not defined in this General Release have the meanings ascribed to such terms in the Employment Agreement. 

9. This General Release may be executed by the parties in one or more counterparts, each of which shall be an original and all of which shall together
constitute one and the same instrument. Each counterpart may be delivered by facsimile transmission or e-mail (as a .pdf, .tif or similar un-editable attachment), which transmission shall be deemed delivery of an originally executed
counterpart hereof. 
  

	1
	 In the event the Company determines that Employee’s termination constitutes “an exit incentive or other employment termination program
offered to a group or class of employees” under the ADEA, the Company will provide Employee with: (1) forty-five (45) days to consider the General Release; and (2) the disclosure schedules required for an effective release
under the ADEA. 

  

 15 

 IN WITNESS WHEREOF, the parties hereto have executed this General Release as of the day and
year first above written. 
  

			
	INSPIRE PHARMACEUTICALS, INC.:
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	EXECUTIVE:
	
	  

	Name:	 	

  

 16 

 Exhibit B 

EMPLOYEE CONFIDENTIALITY, INVENTION ASSIGNMENT 

AND NON-COMPETE AGREEMENT 

THIS EMPLOYEE CONFIDENTIALITY, INVENTION ASSIGNMENT AND NON-COMPETE AGREEMENT (“Agreement”) is made as of the date set
forth on the signature page below between Inspire Pharmaceuticals, Inc. (“Inspire”), and Charles Johnson (“Employee”). 

In consideration of Employee’s employment or continued employment by Inspire, with the intention that this Agreement shall apply to
the entire period of Employee’s employment with Inspire (including the period prior to the date of this Agreement), Employee hereby agrees as follows: 

23. CONFIDENTIAL INFORMATION DEFINED. “Confidential Information” means trade secrets, proprietary information and materials, and
confidential knowledge and information which includes, but is not limited to, matters of a technical nature (such as discoveries, ideas, concepts, designs, drawings, specifications, techniques, models, diagrams, test data, scientific methods and
know-how, and materials such as reagents, substances, chemical compounds, subcellular constituents, cell or cell lines, organisms and progeny, and mutants, derivatives or replications derived from or relating to any of the foregoing materials), and
matters of a business nature (such as the identity of customers and prospective customers, the nature of work being done for or discussed with customers or prospective customers, suppliers, marketing techniques and materials, marketing and
development plans, pricing or pricing policies, financial information, plans for further development, and any other information of a similar nature not available to the public). 

“Confidential Information” shall not include information that: (a) was in Employee’s possession or in the public
domain before receipt from the Company, as evidenced by the then existing publication or other public dissemination of such information in written or other documentary form; (b) becomes available to the public through no fault of Employee;
(c) is received in good faith by Employee from a third party who is known to the Employee to be not subject to an obligation of confidentiality to the Company or any other party; or (d) is required by a judicial or administrative authority
or court having competent jurisdiction to be disclosed by Employee, provided that Employee shall promptly notify the Company and not attempt to prevent the Company from opposing or limiting such order. 

24. NON-DISCLOSURE OF CONFIDENTIAL INFORMATION OF INSPIRE. Employee acknowledges that, during the period of Employee’s employment with
Inspire, Employee has had or will have access to Confidential Information of Inspire. Therefore, Employee agrees that both during and after the period of Employee’s employment with Inspire, Employee shall not, without the prior written approval
of Inspire, directly or indirectly (a) reveal, report, publish, disclose or transfer any Confidential Information of Inspire to any person or entity, or (b) use any Confidential Information of Inspire for any purpose or for the benefit of
any person or entity, except in the good faith performance of Employee’s work for Inspire. 
  

 17 

 25. NON-DISCLOSURE OF CONFIDENTIAL INFORMATION OF OTHERS. Employee acknowledges that, during the
period of Employee’s employment with Inspire, Employee may have had or will have access to Confidential Information of third parties who have given Inspire the right to use such Confidential Information, subject to a non-disclosure agreement
between Inspire and such third party. Therefore, Employee agrees that both during and after the period of Employee’s employment with Inspire, Employee shall not, without the prior written approval of Inspire, directly or indirectly
(a) reveal, report, publish, disclose or transfer any Confidential Information of such third parties to any person or entity, or (b) use any Confidential Information of such third parties for any purpose or for the benefit of any person or
entity, except in the good faith performance of Employee’s work for Inspire or to comply with an order from any court of competent jurisdiction. 

26. PROPERTY OF INSPIRE. Employee acknowledges and agrees that all Confidential Information of Inspire and all reports, drawings, blueprints,
materials, data, code, notes and other documents and records (other than Employee’s personal address book), whether printed, typed, handwritten, videotaped, transmitted or transcribed on data files or on any other type of media, and whether or
not labeled or identified as confidential or proprietary, made or compiled by Employee, or made available to Employee, during the period of Employee’s employment with Inspire (including the period prior to the date of this Agreement) concerning
Inspire’s Confidential Information are and shall remain Inspire’s property and shall be delivered to Inspire within five (5) business days after the termination of such employment with Inspire or at any earlier time on request of
Inspire. Employee shall not retain copies of such Confidential Information, documents and records. 
 27. PROPRIETARY NOTICES. Employee
shall not, and shall not permit any other person to, remove any proprietary or other legends or restrictive notices contained in or included in any Confidential Information. 

28. INVENTIONS. 
 28.1
Employee shall promptly, from time to time, fully inform and disclose to Inspire in writing all inventions, copyrightable material, designs, improvements and discoveries of any kind which Employee now has made, conceived or developed (including
prior to the date of this Agreement), or which Employee may later make, conceive or develop, during the period of Employee’s employment with Inspire, which pertain to or relate to Inspire’s business or any of the work or businesses carried
on by Inspire (“Inventions”). This covenant applies to all such Inventions, whether or not they are eligible for patent, copyright, trademark, trade secret or other legal protection; and whether or not they are conceived and/or developed
by Employee alone or with others; and whether or not they are conceived and/or developed during regular working hours; and whether or not they are conceived and/or developed at Inspire’s facility or not. 

28.2 Inventions shall not include any inventions made, conceived or developed by Employee prior to Employee’s employment with
Inspire, a complete list of which is set forth on Schedule A attached. 
 28.3 All Inventions shall be the sole and exclusive
property of Inspire, and shall be deemed part of the Confidential Information of Inspire for purposes of this Agreement, whether 

 

 18 

 
or not fixed in a tangible medium of expression. Employee hereby assigns all Employee’s rights in all Inventions and in all related patents, copyrights and trademarks, trade secrets and
other proprietary rights therein to Inspire. Without limiting the foregoing, Employee agrees that any copyrightable material shall be deemed to be “works made for hire” and that Inspire shall be deemed the author of such works under the
United States Copyright Act, provided that in the event and to the extent such works are determined not to constitute “works made for hire”, Employee hereby irrevocably assigns and transfers to Inspire all right, title and interest in such
works. 
 28.4 Employee shall assist and cooperate with Inspire, both during and after the period of Employee’s employment
with Inspire, at Inspire’s sole expense, to allow Inspire to obtain, maintain and enforce patent, copyright, trademark, trade secret and other legal protection for the Inventions. Employee shall sign such truthful documents, and do such things
necessary, to obtain such protection and to vest Inspire with full and exclusive title in all Inventions against infringement by others. Employee hereby appoints the Secretary of Inspire as Employee’s attorney-in-fact to execute any truthful
documents on Employee’s behalf for this purpose. 
 28.5 Employee shall not be entitled to any additional compensation for
any and all Inventions made during the period of Employee’s employment with Inspire. 
 29. COVENANT NOT TO COMPETE. If Employee is,
at any time during Employee’s period of employment with Inspire, employed in the discovery or development areas of the Company in a non-clerical position, or as a director level or higher level senior manager of the Company, then this
Section 7 shall apply. Employee and Inspire agree that the services rendered by the Employee are unique and irreplaceable, and that competitive use and knowledge of any Confidential Information would substantially and irreparably injure
Inspire’s business, prospects and good will. Employee and Inspire also agree that Inspire’s business is global in nature due to the type of products and/or services being provided. Therefore, Employee agrees that during the period of
Employee’s employment with Inspire and for a period of one (1) year thereafter, Employee shall not, directly or indirectly, through any other person, firm, corporation or other entity (whether as an officer, director, employee, partner,
consultant, holder of equity or debt investment, lender or in any other manner or capacity): 
 29.1 Research, develop, sell,
market, offer to sell products and/or services anywhere in the world that have the same or similar technological approach or technology platform (e.g., same receptors (such as P2Y), same or similar mechanism of action (such as mucociliary
clearance)) or have the same or similar indication as those being researched, developed, offered, sold, marketed or offered by Inspire during the period of Employee’s employment with Inspire and on the date of the termination of Employee’s
employment with Inspire for any reason; 
 29.2 solicit, induce, encourage or attempt to induce or encourage any employee or
consultant of Inspire to terminate his or her employment or consulting relationship with Inspire, or to breach any other obligation to Inspire (other than advertising not specifically targeted at the Company’s employees and serving as a
reference upon request), however, notwithstanding the foregoing, Employee may engage in the activities described in this Section 7(b) with respect to one executive who worked with Employee in the past and joined the Company without it violating
this provision; and 
  

 19 

 29.3 interfere with, disrupt, alter or attempt to disrupt or alter the relationship,
contractual or otherwise, between Inspire and any consultant, contractor, customer, potential customer, or supplier of Inspire. 

Employee acknowledges that the foregoing geographic, activity and time limitations contained in this Section 7 are reasonable and
properly required for the adequate protection of Inspire’s business. In the event that any such geographic, activity or time limitation is deemed to be unreasonable by a court, Employee shall submit to the reduction of either said activity or
time limitation to such activity or period as the court shall deem reasonable. In the event that Employee is in violation of the aforementioned restrictive covenants, then the time limitation thereof shall be extended for a period of time equal to
the pendency of such proceedings, including appeals. 
 30. DISCLOSURE OF THIS AGREEMENT. Employee hereby authorizes Inspire to notify
others, including but not limited to customers of Inspire and any of Employee’s future employers, of the terms of this Agreement and Employee’s responsibilities under this Agreement. 

31. SPECIFIC PERFORMANCE. Employee acknowledges that money damages alone would not adequately compensate Inspire in the event of a breach or
threatened breach by Employee of this Agreement, and that, in addition to all other remedies available to Inspire at law or in equity, Inspire shall be entitled to injunctive relief for the enforcement of its rights and to an accounting of profits
made during the period of such breach. 
 32. NO RIGHTS GRANTED. Employee understands that nothing in this Agreement shall be deemed to
constitute, by implication or otherwise, the grant by Inspire to the employee of any license or other right under any patent, patent application or other intellectual property right or interest belonging to Inspire. 

33. SEVERABILITY. 
 33.1
Each of the covenants provided in this Agreement are separate and independent covenants. If any provision of this Agreement shall be determined to be invalid or unenforceable, the remainder of this Agreement shall not be affected thereby and any
such invalid or unenforceable provision shall be reformed so as to be valid and enforceable to the fullest extent permitted by law. 

33.2 It is not a defense to the enforcement of any provision of this Agreement that Inspire has breached or failed to perform any
obligation or covenant hereunder or under any other agreement or understanding between Employee and Inspire. 
 34. GOVERNING LAW. This
Agreement shall be governed by and construed in accordance with the laws of the State of North Carolina without regard to conflict of law rules. All suits and claims shall be made only in state or federal courts located in North Carolina.

 35. SUPERSEDES OTHER AGREEMENTS. This Agreement contains the entire agreement of the parties with respect to subject matter hereof and
supersedes all previous agreements and understandings between the parties with respect to its subject matter. 
  

 20 

 36. AMENDMENTS. This Agreement may not be changed, modified, released, discharged, abandoned or
otherwise terminated in whole or in part except by an instrument in writing, agreed to and signed by the Employee and a duly authorized officer of Inspire. 

37. ACKNOWLEDGEMENTS. THE EMPLOYEE ACKNOWLEDGES THAT (i) THE EMPLOYEE HAS READ AND FULLY UNDERSTANDS THIS AGREEMENT; (ii) THE EMPLOYEE HAS
BEEN GIVEN THE OPPORTUNITY TO ASK QUESTIONS; (iii) THE EMPLOYEE HAS RECEIVED A COPY OF THIS AGREEMENT, THE ORIGINAL OF WHICH WILL BE RETAINED IN THE EMPLOYEE’S PERSONNEL FILE; AND (iv) THE EMPLOYEE’S OBLIGATIONS UNDER THIS
AGREEMENT SURVIVE THE TERMINATION OF THE EMPLOYEE’S EMPLOYMENT WITH INSPIRE FOR ANY REASON. 
 IN WITNESS
WHEREOF, the parties have executed this Agreement as of the date set forth below. 
  

			
	 INSPIRE PHARMACEUTICALS, INC.

4222 Emperor Boulevard
 Durham, North Carolina
27703

		
	By:	 	  

		 	(Print Name)
		
		 	  

		 	(Signature Here)
		
	Date:	 	  

	
	EMPLOYEE: Charles Johnson
		
		 	  

		 	(Signature Here)
		
	Date:	 	  

  

 21Consulting Agreement dated effective June 15, 2010

 Exhibit 10.1 

CONSULTING AGREEMENT 

THIS CONSULTING AGREEMENT (the “Agreement”), dated as of June 15, 2010, (the “Effective Date”), is by and between
Pro-Pharmaceuticals, Inc., a Nevada corporation, with a principal place of business at 7 Wells Avenue, Newton, MA 02459 and its successors, subsidiaries and affiliates (collectively, the “Company”), and PGT BioMedical Consulting,
LLC, with a principal place of business at 828 Flamingo Rd, #207, Las Vegas, NV, 89119, (“Consultant”). 
 W I T
N E S S E T H 
 WHEREAS, the Company desires to have the benefit of Consultant’s knowledge and experience, and Consultant
desires to provide consulting and advisory services to the Company, all as hereinafter provided in this Agreement; 
 NOW,
THEREFORE, in consideration of the foregoing premises and mutual agreements hereinafter set forth, the Company and Consultant hereby agree as follows: 
  

	 	1.	Consultation. The Company shall retain Consultant as a non-exclusive consultant and advisor, and Consultant shall serve the Company as a consultant and advisor
upon the terms and conditions hereinafter set forth. The Consultant agrees that Dr. Traber shall provide the services contemplated by this Agreement, and that the Company shall have the right to terminate this Agreement if the services
contemplated hereby are not provided by Dr. Traber and that for the purposes of this Agreement the term “Consultant,” as appropriate, shall mean Dr. Traber. 

 

	 	2.	Term. Subject to the terms and conditions hereinafter set forth, the term of Consultant’s consulting arrangement hereunder (hereinafter referred to as the
“Consultation Period”) shall commence on the Effective Date, and shall continue for a period of four (4) years from the Effective Date. This agreement is renewable by agreement of both parties. 

 

	 	3.	Consulting Duties. 

 3.1
During the Consultation Period, Consultant shall render to Company or to Company’s designee such consulting and advisory services in its areas of expertise and knowledge related to the role of Chief Medical Officer and all associated
responsibilities as outlined in Appendix 1. 
 3.2 Consultant agrees to provide the necessary effort to accomplish mutually
agreed tasks. All work to be performed by Consultant for the Company shall be under the general supervision of the Company. The Consultant will: 

3.3 Complete a “Strategic Plan” for Drug Development and Approval, with the objective of gaining multiple approvals for DAVANAT
in the field of oncology. 
 3.4 Complete a “Strategic Plan” for the Development and Approval of a drug for liver
fibrosis/cirrhosis with the objective of entering into a partnership to run and fund for the human clinical trials. 

 3.5 Consultant shall devote its best efforts and ability to the performance of the duties
attaching to this obligation. 
 3.6 Performance will be measured by the progress of the Phase III clinical trial and approval
process for DAVANAT and the IND for fibrosis. 
 3.7 Consultant’s performance against milestones and project plans will be
reviewed every six (6) months. 
 3.8 In performing its services hereunder, Dr. Peter Traber shall familiarize himself
with and consider, among other things, the history and the nature of the technology of the Company; the condition and prospects of the technology; the operations; preclinical and clinical trial results, prospects of the Company; and such other
factors Dr. Peter Traber deems relevant. 
 3.9 The Company acknowledges that the ability of Dr. Peter Traber to
perform his services is in large part dependent on the Company furnishing Dr. Peter Traber with information regarding the Company in a timely fashion. 

Consultant shall furnish the Company with a statement of activity and progress to milestones at least monthly. 

 

	 	4.	Compensation. 

 4.1
Cash Fees. In consideration for consulting services and agreements hereunder, during the Consultation Period, the Company shall pay to Consultant consulting fees for the time expended rendering services under this agreement, at the rate of
$5,000 per month for the first two years of this agreement, plus the warrants referred to hereinafter in Paragraph 4.2.1. 
 4.2
Compensation. In consideration for consulting services relating specifically to business and/or corporate development activities during the Consultation Period, the ‘Transaction Term’, the Company shall pay to Consultant the
following; 
 4.2.1 Equity Compensation. In exchange for the performance of consulting services relating to this
agreement, the Company shall grant to Consultant long term Incentive warrants (the “Warrants”) exercisable to purchase shares of the Company’s common stock (the “Warrant Shares”) having the terms stated in
4.2.2.1 upon the vesting schedule as follows: 
 a. 150,000 Warrants at the signing of this agreement; 

b. 150,000 Warrants at completion of the first year and satisfactory performance to objectives of this contract; 

c. 150,000 Warrants when the first patient is dosed in the Phase III trial; 

d. 150,000 Warrants when an IND is received for fibrosis. 

4.2.2.1 Terms of Warrants and Issuance Thereof. The issuance of the Warrants is subject to approval of the Company’s Board
of Directors. The Warrants relative to Section 4.2.1(a) - (e) 

 
shall be contained in one instrument, issued following approval of the Board of Directors and in any event no later than 60 days after the Effective Date, with vesting dates that reflect the
respective milestones stated in 4.2.1 (a) - (e) respectively. All Warrants shall contain a “cashless” exercise provision and be exercisable until the fifth anniversary of the date of grant at an exercise price which is the greater of $0.50
or the price of the Company’s common stock on the date of the BOD approval, and remain exercisable through such 5-year term whether or not this Agreement is then in effect. The warrants are exercisable solely for cash (i.e., not the claimed
value of services) in case the Consultant wishes to exercise and take possession of the common stock shares; or “cashlessly” when in-the-money. 

4.2.2.2 Securities Law Matters. The Consultant acknowledges and agrees that (i) neither the Warrants nor the Warrant Shares
issuable thereunder have been or will be registered under the Securities Act of 1933, as amended (the “Securities Act”) or applicable state law and, (ii) the Warrants and Warrant Shares are “restricted securities” as
defined in Rule 144 under the Securities Act (“Rule 144”), and, accordingly, may not be resold or otherwise transferred unless registered or in a transaction exempt from the registration requirements under the Securities Act or
applicable state law; (iii) the Warrants may not be exercised unless pursuant to an applicable exemption under the Securities Act and applicable state law at the time of exercise, (iv) resale of restricted securities such as the Warrant
Shares pursuant to Rule 144, if available, requires compliance with such rule including the holding period thereunder; and (v) the Company has no obligation to register the Warrants or Warrant Shares under the Securities Law or applicable state
law. The Consultant agrees that any transferee or assignee of the Warrants shall be required to acknowledge and agree to be bound by the matters set forth in this Section 4.2.2.2. 

 

	5.	Benefits. Consultant shall not be entitled to any benefits, coverage or privileges, including, without limitation, social security, unemployment, medical or
pension payments, made available to employees of the Company. 

  

	6.	Termination. Either party to this Agreement may terminate this Agreement at any time by giving to the other party written notice of termination with ninety
(90) days notice. If this Agreement is terminated on account of breach of any of the terms and conditions of this Agreement by Consultant, Consultant shall not receive any compensation under this Agreement, either in respect to the Transactions
already entered into on the date of such termination or the Transactions that will be entered into after the date of such termination. The Engagement may be terminated (except as provided above with respect to reimbursement of expenses and
indemnification and earned compensation including any and all warrants) by the Company or Dr. Peter Traber at any time after the third month anniversary of the signing of the agreement, with or without cause, upon 90 days prior written notice
to the other party. 

  

	7.	Cooperation. Consultant shall use its best efforts in the performance of its obligations under this Agreement. The Company shall provide such access to its
information and property as may be reasonably required in order to permit Consultant to perform its obligations hereunder. 

	8.	Inventions and Proprietary Information. 

Inventions. 

All ideas, concepts, discoveries, inventions, developments, original works of authorship, software and system documentation, trade
secrets, methods, tangible research materials, data, information, technology, designs, innovations, improvements and know-how (whether or not patentable) related to the business of the Company (“Inventions”) which are made, devised,
invented, conceived, reduced to practice or tangible medium, created, written, designed or developed by Consultant, solely or jointly with others and whether during normal business hours or otherwise, during the Consultation Period or thereafter if
resulting directly from Proprietary Information of the Company (as defined below), shall be the sole property of the Company. Consultant hereby assigns to the Company all Inventions and any and all related patents, copyrights, trademarks and other
industrial and intellectual property rights and applications therefore, in the United States and elsewhere and appoints any officer of the Company as its duly authorized attorney to execute, file, prosecute and protect the same before any government
agency, court or authority. Upon the request of the Company and at the Company’s expense, Consultant shall execute such further assignments, documents and other instruments as may be necessary or desirable to fully and completely assign all
Inventions to the Company and to assist the Company in applying for, obtaining and enforcing patents or copyrights or other rights in the United States and in any foreign country with respect to any Invention. 

 

	9.	Proprietary Information. 

Consultant acknowledges that its relationship with the Company is one of high trust and confidence and that in the course of its service
to the Company he will have access to and contact with Proprietary Information (as defined in subparagraph 8.2.3. below). Consultant acknowledges that all Proprietary Information, whether or not in writing and whether or not labeled or identified as
confidential and proprietary, is and shall remain the exclusive property of the Company or the third party providing such information to Consultant or the Company. 

Consultant agrees that Consultant shall not, during the Consultation Period and thereafter, publish, disclose or otherwise make available
to any third party, other than employees of the Company, any Proprietary Information except as expressly authorized in writing by the Company. Consultant agrees that Consultant shall use such Proprietary Information only in the performance of its
services for the Company and in accordance with any Company policies with respect to the protection of Proprietary Information. Consultant agrees not to use such Proprietary Information for its own benefit or for the benefit of any other person or
business entity. 
 For purposes of this Agreement, Proprietary Information shall mean, by way of illustration and not
limitation, all information (whether or not patentable and whether or not copyrightable) owned, possessed or used by the Company, including, without limitation, any invention, trade secrets, technical information,

 
know-how, research and development activities of the Company, product and marketing plans, customer and supplier information, apparatus, equipment, process, system, formula, design, non-public
information concerning FDA proceedings, report, tangible research materials, technology, business plan, forecast and information disclosed to the Company or to Consultant by third parties of a proprietary or confidential nature or under an
obligation of confidence, that is communicated to, learned of, developed or otherwise acquired by Consultant in the course of its service as a consultant to the Company. 

Consultant’s obligations under this Section 8.2 shall not apply to any information that (i) is or becomes generally known
within the Company’s industry under circumstances involving no breach by Consultant of the terms of this Section 8.2, or (ii) was known to Consultant at the time it was disclosed as evidenced by Consultant’s written records at
the time of disclosure. 
 Consultant agrees to exercise all reasonable precautions to protect the integrity and confidentiality
of Proprietary Information in his possession and not to remove any materials containing Proprietary Information from the Company’s premises except to the extent necessary to his performance of consulting services for the benefit of the Company.
Upon termination of this Agreement or at any other time upon request by the Company, Consultant shall promptly deliver to the Company all records, files, memoranda, notes, designs, data, tangible research materials, reports, customer lists,
drawings, plans, sketches, laboratory and research notebooks and other documents (and all copies or reproductions of such materials) relating to the business of the Company. 

Consultant shall not disclose to the Company any trade secrets or confidential or proprietary information of any other party. 

 

	10.	Independent Contractor Status. 

Consultant shall perform all services under this Agreement as an “independent contractor” and not as an employee or agent of the
Company. Consultant is not authorized to assume or create any obligation or responsibility, express or implied, on behalf of, or in the name of, the Company or to bind the Company in any manner. 

 

	11.	Confidentiality Consultant understands the confidential nature of the information and materials he will acquire or develop in performing its services under this
Agreement. Consultant acknowledges that if such information or materials were revealed to competitors of the Company, then such disclosure could cause damage to the Company, and agrees that Consultant shall not disclose, during the Consultation
Period and for five (5) years thereafter, any Proprietary Information to competitors of the Company. 

  

	12.	Notices. All notices required or permitted under this Agreement shall be in writing delivered by a recognized national overnight courier, personal delivery, or
facsimile transmission and shall be deemed effective upon receipt. The parties shall designate their addresses and facsimile numbers. 

	13.	Entire Agreement. This Agreement, including all schedules and exhibits attached hereto, constitutes the entire agreement between the parties and supersedes all
prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement. 

  

	14.	Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and Consultant. 

 

	15.	Governing Law. This Agreement shall be construed, interpreted and enforced in accordance with the laws of the Commonwealth of Massachusetts.

  

	16.	Successors and Assigns. This Agreement shall be binding upon, and inure to the benefit of, both parties and their respective successors and assigns, including
any corporation with which, or into which, the Company may be merged or which may succeed to its assets or business, provided, however, that the obligations of Consultant are personal and shall not be assigned by him. 

 

	17.	Miscellaneous. 

  

	 	17.1	The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this
Agreement. 

  

	 	17.2	In the event that any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal, or unenforceable in any
respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, and all other provisions shall remain in full force and effect. If any of the provisions of this Agreement is held to be excessively
broad, it shall be reformed and construed by limiting and reducing it so as to be enforceable to the maximum extent permitted by law. 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set forth above. 

 

					
	For Pro-Pharmaceuticals
		
	By:	 	 /s/    Theodore D. Zucconi

		 	Theodore D. Zucconi, Ph.D.,
		 	Chief Executive Officer
	
	For PGT BioMedical Consulting
		
	By:	 	 /s/    Dr. Peter Traber

	
	Dr. Peter Traber for Consultant
		
	Title:	 	  

 Appendix 1 

General Roles and Responsibilities of Consultant as acting CMO 

Regulatory Strategy Definition; 
 FDA Interface
management; 
 Clinical Trial Strategy Definition and Execution; 

Management of internal and external Resources; 

Assistance with Road Shows and Presentations to Possible Investors; 

Assistance with Investor Relations; 
 Other
General Duties as Assigned by the CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]